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Lack of Concordance in Parapneumonic Effusion
Management in Children in Central Europe
Gaudenz M. Hafen, MD,1* Andrea-Claudia Grenzbach, MD,2* Alexander Moeller, MD,3
and Mascha K. Rochat, MD4
Summary. Treatment of parapneumonic effusion in children remains controversial in the
literature and in clinical practice. The aim of this study was to determine whether mutual
consensus exists in the diagnosis and treatment of parapneumonic effusion in Central European
countries. A questionnaire was sent to all directors of pediatric respiratory units in four adjacent
Central European countries (Austria, France, Germany, Switzerland). The response rate was
61.8%. Responses reflected acceptable agreement regarding initial diagnostic procedures, as
most centers performed chest X-ray and biological exams, followed by ultrasound, thoracocent-
esis, or computed tomography. However, antibiotic regimens were very heterogeneous, and the
survey revealed complete lack of agreement on the indications and effusion volume threshold for
invasive procedures, such as fibrinolytic instillation and thoracoscopy. In conclusion, apart from
initial diagnostic procedures, this study showed a lack of mutual consensus among the four
countries regarding the management of pediatric parapneumonic effusion. Multicenter
prospective trials are clearly needed to acquire more evidence on the management of childhood
parapneumonic effusion, enabling the development of evidence-based algorithms that could help
to avoid unnecessary examinations with potential long-term side effects, such as radiation
exposure at a young age. Pediatr Pulmonol.  2015 Wiley Periodicals, Inc.
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INTRODUCTION
Parapneumonic effusion (PE) is defined as any pleural
effusion that is secondary to pneumonia—bacterial or
viral—or lung abscess.1 In children, PE is associated with
high morbidity, but low mortality2; independent of the
treatment modality, the long-term consequences for
children are negligible, as the outcome in most cases is
full recovery.3
Although the British Thoracic Society (BTS) published
in 2005 national guidelines for the management of pleural
infection in children,4 the treatment of choice remains a
matter of controversy in the literature and in clinical
practice. While several studies have compared operative
and non-operative approaches,5–8 published evidence on
the correct diagnosis and treatment of PE is scarce,9 and
clinical experience suggests the presence of heterogeneity
between and within pediatric respiratory centers. Data on
the extent of this heterogeneity are lacking. The diagnosis
and treatment of PE have clinical and financial
implications, as they may involve irradiation, antibacteri-
al therapy, and invasive procedures. The development of
evidence-based guidelines would be thus of interest for
three main reasons.
Firstly, although radiation exposure is a concern in
adults and children, the risk of radiation-related cancer
development can be several times higher in children than
in adults exposed to identical computed tomography (CT)
examinations.10 Given the likelihood that no low-dose
radiation “threshold” for cancer induction exists, no
amount of radiation should be considered to be absolutely
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safe.11 Thus, evidence-based guidelines for the diagnosis
and treatment of PE may reduce excessive exposure to
radiation at a young age, as current diagnosis often
involves lung CTand patients likely undergo repeated CT
examination during the evolution of the disease.
Secondly, evidence-based consensus may allow ade-
quate antibacterial therapy, reducing the risk of resistance
development and overtreatment leading to side effects.
Lastly, guidelines may help to avoid unnecessary
invasive procedures in children, which may lead to a
reduction in morbidity, healthcare utilization, and
associated costs.
The aim of this study was to determine whether mutual
consensus has been reached on the diagnosis and
treatment of PE in various pediatric pulmonology centers
in adjacent countries. The hypothesis was that such
mutual consensus exists, on the basis of knowledge
transfer due to the exchange of trainees among centers.
Participation of physicians and trainees in the field of
pediatric pulmonology in small national and international
scientific meetings is language dependent and organized
by the French Association de Pneumo-Pediatrie Inter-
Regionale or the German Gesellschaft f€ur P€adiatrische
Pneumologie e.V. This survey addressed the clinical
management of children with PE in hospitals in four
Central European countries with French or German as the
national language.
METHODS
Study Design and Sample
We conducted a questionnaire-based survey on the
diagnosis and treatment of PE in Austria, France,
Germany, and Switzerland. The questionnaire was sent
by mail between July and December 2010 to all directors
of pediatric respiratory centers, based on official country
lists of these centers. Reminders were sent to directors
who did not respond within 6 weeks.
In February 2015, a short Follow up survey was sent to
all centers that had participated in the original study. This
survey assessed specifically centers’ adherence to BTS
guidelines3 for the management of pleural infection in
children.
Questionnaires
A 16-item English-language questionnaire was devel-
oped for the main survey (Supplement 1). The question-
naire took about 15minutes to complete. It was composed
of general (e.g., number of patients per year), diagnostic
(e.g., initial radiological examination used), and treat-
ment (e.g., choice of antibiotics) sections, with a final
item assessing respondents’ interest in participating in a
prospective multicenter study. Items had a structured
response format; most questions were closed, with one
possible answer, but some questions were multiple choice
or offered the option of free-text answers (e.g., duration of
antibiotic therapy, volume of pleural effusion).
In the 2015 Follow up survey the items were “No
changes” or “Yes, we have changed our management of
children with PE since 2010.” In case of “Yes,” the
participants were asked whether the change was to follow
the BTS guidelines or not.
Statistical Analysis
Statistical analysis was performed using SAS 9.3 (SAS
Institute Inc., Cary, NC). Descriptive statistics were
calculated. As not every center responded to every item
and some centers reported multiple diagnosis and/or
treatment methods, not all results add up to 100%.
RESULTS
Of the 110 pediatric pulmonology centers contacted, 68
centers returned the 2010 questionnaire (61.80% response
rate). The response rate varied among countries (Fig. 1). A
median of 10 (min. 2, max. 40) cases of PE were treated
annually per center. In 2010, 35 of 65 (53.85%) centers
reported following the BTS guidelines3 for the manage-
ment of PE in children.
In 2015, 67 of the 68 centers that had participated in
2010 were re-contacted. The response rate to the 2015
survey was 74.62% (50 centers). Country-specific
response rates were 66.66% (2/3) for Austria, 68.42%
(13/19) for France, 68.42% (26/38) for Germany, and
100% (8/8) for Switzerland. As one center closed after
returning the survey, data from 49 centers were analyzed.
Thirty-two centers reported that they had not changed
their management of PE since 2010. In 2015, seven
additional centers reported following the BTS guidelines,
bringing the total to 64.61% (42/65). Other centers
reported changes in management involving the introduc-
tion of new standard operating procedures (three centers)
or individual changes, such as the choice of antibiotics
(seven centers).
Diagnostic Procedures
Upon clinical suspicion of PE, all centers reported
performing the following radiological examinations:
chest X-ray [CXR; 67/68 (98.5%)], ultrasound [US; 55/
68 (80.88%)], ultrasound-guided thoracocentesis or drain
placement [36/68 (52.94%)], andCT [17/68 (25%)]. After
initial radiological examination, 18/67 (26.87%) centers
reported the initiation of antibiotic therapywith no further
imaging study.
In -three (4.41%) centers, antibiotic therapy was
initiated with no initial laboratory examination and PE
evolution was monitored. However, the majority [60/68
(88.24%)] of centers reported performing serum
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biochemistry and differential blood cell counts. Half the
centers performed sputum culture and 44/68 (64.71%)
centers reported performing thoracocentesis. All of these
centers performed Gram staining/culturing of the pleural
fluid obtained by thoracocentesis, 42/44 (95.45%) centers
performed differential cell counts, and 39/44 (88.64%)
centers performed biochemical analyses.
If not performed initially, thoracocentesis was per-
formed based on the sole criterion of the clinical picture or
severity of the illness in 21/66 (31.8%) centers. The
other centers [45/66 (68.2%)] additionally assessed the size
of the pleural effusion by CXR, US, and/or CT. The
estimated size or volume of the pleural effusion was also
used as a criterion for thoracocentesis performance, but this
practice varied among centers (Fig. 2). Only 2/66 (3%)
centers reported performing thoracocentesis for diagnostic
purposes alone. The other centers used the procedure for
fluid evacuation and/or in conjunction with drainage.
Thoracocentesis was performed by pediatric surgeons
[10/66 (15.1%)], pediatricians [10/66 (15.1%)], pediatric
pulmonologists [10/66 (15.1%)], intensivists/anesthetists
[8/66 (12.1%)], and thoracic surgeons [1/66 (1.5%)]. In
27/66 (40.9%) centers, various combinations of physicians
from multiple disciplines were involved. Three (4.41%)
centers reported performing diagnostic bronchoscopy.
Treatment
All (67/67) centers initiated antibiotic therapy intrave-
nously. However, the choice, combination, and duration
of intravenous antibiotic therapy varied among centers
(Fig. 3). Twenty-four centers prescribed oral antibiotics
initially. As for intravenous antibiotics, the choice,
dosage, and duration of oral antibiotic treatment varied
widely (Fig. 4).
Centers reported the consideration of chest drain
insertion in the following cases: significant volume
shown on radiological examinations [50/67 (74.6%)],
increased effusion under conservative treatment [46/67
(68%)], and/or compromised respiratory function [60/67
(89.6%)]. In free-text responses, directors from three
centers reported chest drain insertion in cases of persistent
fever, thick fluid, and empyema, respectively. The criteria
for this invasive procedure varied among centers. Eight of
63 (12.7%) centers reported the use of repeated
thoracocentesis instead of chest drain insertion.
Centers used small-bore percutaneous drains [18/67
(26.9%)], pig-tail catheters [17/67 (25.4%)], and large-
bore surgical drains [21/67 (31.3%)] for chest drainage.
Eleven centers reported the use of more than one of these
drain types. Similar to thoracocentesis, chest drain
insertion was performed by pediatric/thoracic surgeons
[24/68 (35.3%)], pediatricians [7/68 (10.3%)], pediatric
pulmonologists [8/68 (11.8%)], intensivists/anesthetists
[6/68 (8.8%)], and pediatric intensivists [1/68 (1.5%)].
Twenty-two of 68 (32.3%) centers reported the involve-
ment of various physicians from multiple disciplines.
Thorascopy was performed based on the sole criterion
of organized effusion/empyema or unfavorable clinical
evolution in 18/57 (31.6%) and 12/57 (21.1%) centers,
respectively. The remaining centers [27/57 (47.37%)]
reported using a combination of effusion volume
estimated by CXR, US, and/or CT; clinical picture;
unfavorable clinical evolution after three to 30 days; and/
or the presence of organized effusion/empyema. Use of
the estimated size or volume of the pleural effusion as a
criterion for thoracoscopy performance varied among
centers.
Fig. 1. Response rate.
Fig. 2. Estimated size or volume of the pleural effusion as a
criterion to perform a thoracocentesis.
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Fibrinolytics were not used in 29/67 (43%) centers,
always used in 7/67 (10%) centers, and used in certain
cases in 31/67 (46%) centers. Urokinase was used in 33/
38 (87%) centers and streptokinase was used in 2/38 (5%)
centers. Dosages varied widely (Fig. 5) and the durations
ranged from one to five days, with 75% of centers using
3-day regimens.
Almost all (84.6%) centers indicated that theywould be
interested in participating in a prospective, randomized
multicenter study of the management of PE in children.
DISCUSSION
With this questionnaire-based survey, we demonstrated
the lack of mutual consensus on the management of PE in
children in Central European countries. We found
variable diagnostic algorithms, very heterogeneous
antibiotic regimens, and a lack of agreement with regard
to the definitions of thresholds (e.g., effusion volume) and
the use of invasive procedures (e.g., fibrinolytic instilla-
tion, thoracoscopy). This chaotic situation may have
supported the interest of 85% of centers in participating in
a prospective, randomized multicenter study of PE
management in children.
To increase the chance of identifying mutual consensus
due to the exchange of trainees and knowledge, the survey
was conducted in four adjacent European countries:
Austria, France, Germany, and Switzerland. We found
consensus on the initial diagnostic approach, as most
centers performed CXR with biological examinations
(differential cell count, biochemistry), followed by US,
thoracocentesis, and CT, if necessary. An evidence-based
diagnostic algorithm would likely help to avoid unneces-
sary examinations, particularly those associated with
potential long-term side effects, such as radiation
exposure at a young age.
The choice, dosage, and duration of intravenous and
oral antibiotics varied widely among centers. Empirical
Fig. 3. Intravenous antibiotics as single prescription or in combination between two or three
antibiotics. Sixty seven centres given intravenous antibiotics. The number of centres who give a
specific intravenous antibiotics is shown. As many centres given then more than one
intravenous antibiotic the total is >100%. Other: Flucloxacillin, Oxacillin, Piperacillin,
Tazobactum,Cefuroxim,Cefotaxim,Cefotiam, Amikacin, Erythromycin,Meropenem,Rifampicin,
Clindamycin.
Fig. 4. Oral antibiotics as single prescription or in combination between two or three antibiotics.
Twenty four centresgivenoral antibiotics. Thenumberof centreswhogive a specific intravenous
antibiotics is shown.Asmanycentresgiven thenmore thanone intravenousantibiotic the total is
>100%. Other: Cefuroxim, Cefaclor, Clarythromycin, Erythromycin, Actromycin, Ravamycin,
Pristinamycin, Rifampicin, Clindamycin.
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treatment of community-acquired pneumonia must be
active against pneumococcal infection, and should
involve consideration of the local prevalence of
antibiotic resistance, which varies regionally in.12,13 A
2012 European Union survey revealed that 1% to<5% of
invasive isolates of Streptococcus pneumoniae in
Germany and Austria, but 10% to <25% of isolates in
France, were not susceptible to penicillin or macrolides
(2013). In 2013, the overall prevalence of penicillin
resistance in Switzerland was about 15%, but this
prevalence was about 20% in the western (French-
speaking) part of the country.14 Thus, the establishment of
recommendations for antibiotic management across
Europe may be difficult. Moreover, the administration
of pneumococcal conjugate vaccine (PCV) to infants may
have contributed to the significant decrease in antibiotic
resistance levels in 2011, by eliminating infections and
children’s carriage of frequent classic resistant serotypes
(2013).15 Future studies must take this factor into
consideration.
The indications for thoracoscopy and fibrinolytic
instillation were also very heterogeneous among centers.
The responses showed strong consensus, however, on the
choice of urokinase over streptokinase. This preference
makes sense, as urokinase has fewer side effects.16
Streptokinase is associated with side effects such as fever
(although this effect is reversible with discontinuation of
administration),17 and a higher risk of allergic reaction.18
No center participating in our survey reported use of the
new fibrinolytic intrapleural tissue plasminogen activator,
but this product is emerging as a therapeutic option for
children.19,20
The literature shows a lack of consensus on the best
diagnostic and treatment methods for complicated pneu-
monia. In addition, meta-analysis is hampered by different
interpretations of “conservative” or “non-operative”
treatment, given the lack of clear definitions. For example,
Avansino et al.5 defined “primary non-operative therapy”
as “children being treated initially with antibiotics and
thoracocentesis and/or tube thoracotomy,” although most
physicians would consider thoracocentesis and thoracoto-
my to be operative interventions. In a large retrospective
analysis of an administrative database, Goldin et al.3
recently showed that half of more than 14,000 children
hospitalized with effusion/empyema between 2003 and
2008 required only intravenous antibiotic therapy, raising
the question of the degree of invasiveness required. In a
systematic analysis of randomized controlled trials
involving fibrinolytic use, Krenke et al.9 found only minor
evidence for the superiority of fibrinolytics over normal
saline, or for the greater effectiveness of fibrinolytics
compared with thoracoscopy.
Treatment of children with PE is associated with
significant utilization of healthcare resources. Because
healthcare systems differ throughout Europe, examina-
tion choices can be influenced by expense, rather than
evidence.
Few studies have compared the costs of invasive and
non-invasive management. In 2006, Sonnappa et al.8
found that treatment with intrapleural urokinasewasmore
economic than video-assisted thoracoscopic surgery
(VATS). Two years later, Cohen et al.21 postulated that
the use of intrapleural fibrinolytic agents in pediatric
patients reduced the costs associated with the treatment of
empyema. The most recent publication, however, showed
no overall cost difference between VATS and primary
chest tube placement.22
As the outcome of PE is almost always favorable,
independent of treatment, one might argue that the
paucity of evidence for the optimal diagnosis and
management is unimportant. However, the diagnosis
and treatment of PE involve irradiation, antibacterial
therapy, and invasive procedures with clinical and
financial implications. Regrettably, our data do not allow
the development of a flow chart or specific recommen-
dations; however, a more ubiquitous approach to the
management of PE could be obtained by the following
means. First, an update of the 10-year-old BTS guidelines
could be attempted, involving centers that do and do not
follow the guidelines currently. Second, appropriate
multicenter studies might produce evidence to define
thresholds, such as effusion volume, to standardize
procedures, mainly to avoid unnecessary interventions
and the spread of antibiotic resistance. Finally, the
establishment of a pan-European network guided by the
European Respiratory Society (ERS) could be consid-
ered. Such a consortium would need to consider regional
and national characteristics (e.g. antibiotic resistance),
and include representatives from national pediatric
pulmonology societies to increase adherence to the
resulting recommendations.
Surprisingly, we discovered that three centers in our
sample performed diagnostic bronchoscopy in cases of
PE. The BTS guidelines do not recommend the routine
use of this procedure. In addition, some pediatric
Fig. 5. Dosage of Fibrinolytics instilled.
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pulmonology centers reported that they encountered
as few as two patients with PE per year. Given the
likelihood that children with PE are treated in general
pediatric settings as well as pediatric pulmonology
centers, clinical evidence and associated guidelines
would reduce patient burden. The introduction of the
7-valent pneumococcal conjugate vaccine (PCV7) has led
to a significant reduction in the incidence of invasive
pneumococcal diseases, such as pneumonia, septicemia,
and meningitis.23–25 However, PCV7 does not include
the serotypes most commonly responsible for PE. An
increase in the incidence of PE26,2 prompted the
development of a 13-valent PCV.27 With its recent
introduction in clinical practice, the epidemiology of
empyema in children is changing again, as it did after the
introduction of its precursor; the prevalence of PE is
declining,28 at least at present.
Limitations
As this survey was performed in central Europe, the
findings may not be universally valid for all European
countries. We did not include Great Britain in the survey,
as the study was not designed to investigate compliance
with its country-specific BTS guidelines. The question-
naire was sent only to hospitals with pediatric pulmonol-
ogy units, which is a clear study limitation. However,
we selected this approach because we expected
less heterogeneity in pediatric pulmonology units and
we aimed to assess interest in participation in a large
randomized study.
Moreover, this study was limited by the potential
risk for language translation error using an English
questionnaire, and alternative interpretation of survey
items. For example, items pertaining to the timing of
investigation and multiple-choice questions may have
been misinterpreted.
One might also argue that a response rate of 61.80% is
not sufficient. However, although agreement is lacking on
a minimal acceptable response rate, general consensus
holds that at least half of the sample should have
completed the survey instrument.29
With regard to irradiation, the questionnaire did not
elicit exact details about dosage protocols for CXR or CT.
The utilization of ultra-low-dose CT protocols should
certainly be examined in any future prospective study, as
exposure to radiation is of concern, particularly in
children.
Finally, the survey was conducted in 2010, and does
not necessarily reflect the management of PE in 2015.
For that reason, we performed a Follow up study
involving centers that participated in 2010. Only seven
additional centers reported that they followed the BTS
guidelines in 2015. Therefore, the management of PE
remains heterogeneous.
CONCLUSION
In conclusion, this study revealed a lack of mutual
consensus on the management of PE in children in four
adjacent countries. The management of this disease
remains center dependent. Due to the small number
of patients treated in each center, only multicenter
prospective studies can provide better evidence regarding
the appropriate treatment of PE. In any future prospective
study, clear definition of treatment modalities (non-
operative versus operative) and qualitative and quantita-
tive establishment of outcome indicators, such as pain and
respiratory distress, would be important. As we have
shown substantial heterogeneity in the management of PE
in children, we clearly see the need for the establishment
of an ERS or ERS/ATS (American Thoracic Society) task
force to tackle the subject.
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